Symptom-Driven Personalized Proton Pump Inhibitors Therapy Using Bayesian Neural Networks and Model Predictive Control

TL;DR

This paper introduces a noninvasive, personalized PPI therapy framework that uses Bayesian neural networks and model predictive control to optimize drug dosing based on patient symptoms, reducing drug use significantly while maintaining effective acid suppression.

Contribution

It presents a novel symptom-driven, probabilistic control approach combining Bayesian neural networks with MPC for personalized PPI management without invasive measurements.

Findings

Reduces PPI usage by 65% compared to standard regimens

Maintains acid suppression with at least 95% probability

Demonstrates effectiveness across diverse dietary schedules and virtual patients

Abstract

Proton Pump Inhibitors (PPIs) are the standard of care for gastric acid disorders but carry significant risks when administered chronically at high doses. Precise long-term control of gastric acidity is challenged by the impracticality of invasive gastric acid monitoring beyond 72 hours and wide inter-patient variability. We propose a noninvasive, symptom-based framework that tailors PPI dosing solely on patient-reported reflux and digestive symptom patterns. A Bayesian Neural Network prediction model learns to predict patient symptoms and quantifies its uncertainty from historical symptom scores, meal, and PPIs intake data. These probabilistic forecasts feed a chance-constrained Model Predictive Control (MPC) algorithm that dynamically computes future PPI doses to minimize drug usage while enforcing acid suppression with high confidence - without any direct acid measurement. In silico studies over diverse dietary schedules and virtual patient profiles demonstrate that our learning-augmented MPC reduces total PPI consumption by 65 percent compared to standard fixed regimens, while maintaining acid suppression with at least 95 percent probability. The proposed approach offers a practical path to personalized PPI therapy, minimizing treatment burden and overdose risk without invasive sensors.